Gabriella Liszkay

发表

Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.

Dirk Schadendorf, Reinhard Dummer, Naoya Yamazaki, 2018, The Lancet. Oncology.

Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy

Judit Oláh, Z. Lengyel, G. Emri, 2017, Cancer Immunology, Immunotherapy.